CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-03-01 | Kulkarni Samarth Chief Executive Officer | Shares withheld for taxes | −748 | $39.97 | $30K | 166,542 |
| 2019-02-25 | Novak Rodger President | Sale | −14,780 | $40.00 | $591K | 1,033,227 |
| 2019-01-09 | Novak Rodger President | Sale | −82,690 | $35.01 | $2.9M | 1,048,007 |
| 2019-01-08 | Novak Rodger President | Sale | −17,310 | $35.09 | $607K | 1,130,697 |
| 2019-01-02 | Klein Lawrence Otto Chief Business Officer | Grant or award | +20,000 | $29.87 | $597K | 20,000 |
| 2019-01-02 | Klein Lawrence Otto Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-12-27 | Vertex Pharmaceuticals (Europe) Ltd 10% owner | Purchase | +27,461 | $24.95 | $685K | 5,380,940 |
| 2018-12-26 | Vertex Pharmaceuticals (Europe) Ltd 10% owner | Purchase | +12,737 | $24.89 | $317K | 5,353,479 |
| 2018-12-24 | Vertex Pharmaceuticals (Europe) Ltd 10% owner | Purchase | +2,603 | $22.91 | $60K | 5,275,345 |
| 2018-12-24 | Vertex Pharmaceuticals (Europe) Ltd 10% owner | Purchase | +11,742 | $23.18 | $272K | 5,287,087 |
| 2018-12-24 | Vertex Pharmaceuticals (Europe) Ltd 10% owner | Purchase | +53,655 | $24.97 | $1.3M | 5,340,742 |
| 2018-12-21 | Vertex Pharmaceuticals (Europe) Ltd 10% owner | Purchase | +22,742 | $22.58 | $513K | 5,272,742 |
| 2018-12-18 | EMSTER KURT VON Director | Sale | −62,925 | $29.70 | $1.9M | 1,171,268 |
| 2018-12-18 | EMSTER KURT VON Director | Sale | −69,925 | $29.70 | $2.1M | 1,164,268 |
| 2018-12-17 | EMSTER KURT VON Director | Sale | −3,009 | $33.17 | $100K | 1,234,193 |
| 2018-12-07 | Kulkarni Samarth Chief Executive Officer | Option exercise | +21,500 | $1.81 | $39K | 167,290 |
| 2018-12-07 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Options (Right to Buy) | −21,500 | 243,058 | ||
| 2018-12-01 | Kulkarni Samarth Chief Executive Officer | Shares withheld for taxes | −741 | $38.33 | $28K | 145,790 |
| 2018-11-21 | CELGENE CORP /DE/ 10% owner | Sale | −80,000 | $19.25 | $1.5M | 4,173,019 |
| 2018-09-01 | Kulkarni Samarth Chief Executive Officer | Shares withheld for taxes | −741 | $56.67 | $42K | 146,531 |
Page 48 of 62 · 1,221 trades